» Articles » PMID: 9463314

ATM Mutations and Phenotypes in Ataxia-telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast Cancer

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 1998 Apr 16
PMID 9463314
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

We report the spectrum of 59 ATM mutations observed in ataxia-telangiectasia (A-T) patients in the British Isles. Of 51 ATM mutations identified in families native to the British Isles, 11 were founder mutations, and 2 of these 11 conferred a milder clinical phenotype with respect to both cerebellar degeneration and cellular features. We report, in two A-T families, an ATM mutation (7271T-->G) that may be associated with an increased risk of breast cancer in both homozygotes and heterozygotes (relative risk 12.7; P=. 0025), although there is a less severe A-T phenotype in terms of the degree of cerebellar degeneration. This mutation (7271T-->G) also allows expression of full-length ATM protein at a level comparable with that in unaffected individuals. In addition, we have studied 18 A-T patients, in 15 families, who developed leukemia, lymphoma, preleukemic T-cell proliferation, or Hodgkin lymphoma, mostly in childhood. A wide variety of ATM mutation types, including missense mutations and in-frame deletions, were seen in these patients. We also show that 25% of all A-T patients carried in-frame deletions or missense mutations, many of which were also associated with expression of mutant ATM protein.

Citing Articles

Two founder variants account for over 90% of pathogenic BRCA alleles in the Orkney and Shetland Isles in Scotland.

Kerr S, Klaric L, Muckian M, Cowan E, Snadden L, Tzoneva G Eur J Hum Genet. 2024; 32(12):1624-1631.

PMID: 39438716 PMC: 11607322. DOI: 10.1038/s41431-024-01704-w.


Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants.

Richardson M, Holdren M, Brannan T, de la Hoya M, Spurdle A, Tavtigian S Am J Hum Genet. 2024; 111(11):2411-2426.

PMID: 39317201 PMC: 11568761. DOI: 10.1016/j.ajhg.2024.08.022.


Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline sequence variants.

Richardson M, Holdren M, Brannan T, de la Hoya M, Spurdle A, Tavtigian S medRxiv. 2024; .

PMID: 38854136 PMC: 11160822. DOI: 10.1101/2024.05.28.24307502.


Evaluation of Ataxia-Telangiectasia Mutated IVS10 Mutation in Breast Cancer Along with Clinicopathological Parameters.

Ahuja S, Aneja H, Yadav A, Ranga S, Chintamani , Paul J J Midlife Health. 2024; 14(4):272-279.

PMID: 38504739 PMC: 10946688. DOI: 10.4103/jmh.jmh_71_23.


Variant ataxia telangiectasia identified during evaluation for short stature.

Sokay A, Leahy T, ORegan M, O Grady M BMJ Case Rep. 2024; 17(3).

PMID: 38453233 PMC: 10921506. DOI: 10.1136/bcr-2023-257736.


References
1.
Swift M, Morrell D, Cromartie E, Chamberlin A, Skolnick M, Bishop D . The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986; 39(5):573-83. PMC: 1684065. View

2.
Ying K, Decoteau W . Cytogenetic anomalies in a patient with ataxia, immune deficiency, and high alpha-fetoprotein in the absence of telangiectasia. Cancer Genet Cytogenet. 1981; 4(4):311-7. DOI: 10.1016/0165-4608(81)90027-3. View

3.
Swift M, Morrell D, Massey R, Chase C . Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991; 325(26):1831-6. DOI: 10.1056/NEJM199112263252602. View

4.
Easton D . Cancer risks in A-T heterozygotes. Int J Radiat Biol. 1994; 66(6 Suppl):S177-82. DOI: 10.1080/09553009414552011. View

5.
Liu Q, Sommer S . Restriction endonuclease fingerprinting (REF): a sensitive method for screening mutations in long, contiguous segments of DNA. Biotechniques. 1995; 18(3):470-7. View